~~<i id='08CB6E4C08'><strike id='08CB6E4C08'><tt id='08CB6E4C08'><pre id='08CB6E4C08'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：hotspot 2025-09-29 01:54:37 Page View：735

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Will the FTC rein in IQVIA's health data empire?
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

explore

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

Rise in cancer among younger people worries and puzzles doctors

Atumorinvasionintoaveininacaseofcolorectalcancer.WikimediaCommonsWhenboththenurseandthe doctorbroked

Medicare proposal to cover medical devices draws a mixed reaction

AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

Did you have Obamacare on your GOP debate bingo card?

AlexHogan/STATYou’rereadingthewebeditionofD.C.Diagnosis. Signuphere toreceivethisnewsletterinyourinb